List view / Grid view
20 March 2014 | By GlaxoSmithKline
GSK will continue the trial in order to assess the third co-primary endpoint, which is disease-free survival in a gene signature positive sub-population...
20 March 2014 | By AstraZeneca
AstraZeneca announced that Ann Cairns will be proposed to shareholders for election as a Non-Executive Director at the Company’s Annual General Meeting on 24 April 2014...
20 March 2014 | By Pfizer Inc.
Pfizer intends to submit biologics license application for bivalent rLP2086 to U.S. Food and Drug Administration by mid-2014...
19 March 2014 | By Janssen
Additional Phase 3 data from the QUEST-1, QUEST-2 and PROMISE studies explore potential of simeprevir in genotype 1 hepatitis C patients while new ATTAIN data demonstrate a superior safety profile for simeprevir...
19 March 2014 | By The European Medicines Agency
The European Medicines Agency has published its work programme for 2014...
19 March 2014 | By Sanofi
A long-term strategic business collaboration to co-develop and commercialize an innovative vaccine against pneumococcal infection to address global public-health needs...
19 March 2014 | By Pfizer Inc
Pfizer Inc. announced the launch of its fourth integrated annual review, which summarizes the company’s 2013 financial, environmental and social responsibility performance...
19 March 2014 | By Daiichi Sankyo Company
Astellas Pharma Inc. and Daiichi Sankyo Company, Limited announced the companies would form a compound library sharing partnership for approximately 400,000 selected compounds...
18 March 2014 | By Biogen Idec
Biogen Idec announced that the U.S. Food and Drug Administration has extended the initial Prescription Drug User Fee Act date for its review of the Biologics License Application for marketing approval of PLEGRIDY...
18 March 2014 | By Astellas
Roxadustat could change treatment of anaemia associated with CKD and remove the need for multiple injections...
18 March 2014 | By Lundbeck
Denmark is the first country in Europe where Abilify Maintena® is fully reimbursed and accessible to people diagnosed with schizophrenia...
17 March 2014 | By Bristol-Myers Squibb
Five Prime Therapeutics, Inc. and Bristol-Myers Squibb Company announced that they have signed a collaboration agreement for the discovery, development and commercialization of immuno-oncology therapies...
17 March 2014 | By Amgen
Study meets primary endpoint of LDL cholesterol reduction First phase 3 data of a pcsk9 inhibitor in patients with homozygous familial hypercholesterolemia - a rare and serious disease...
14 March 2014 | By GlaxoSmithKline
GlaxoSmithKline plc and Theravance, Inc. announced positive results from three phase III studies...
14 March 2014 | By Novo Nordisk
Novo Nordisk is increasing its drug development capacity by investing 550 million Danish kroner in a new research and development facility in Bagsværd, Denmark...
